Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2025-05-28 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a 'Form 52-109FV2', which is a standard officer certification for interim filings. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like interim filings), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. Q1 2025
2025-05-28 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 90% confidence The document is Form 52-109FV2, a Venture Issuer Basic Certificate filed by the CEO certifying the interim financial report and MD&A for the period ended March 31, 2025, under Canadian securities regulation 52-109. It is not the interim report itself, nor an announcement to shareholders; rather it is a regulatory compliance filing. Therefore, it best fits the fallback category of Regulatory Filings (RNS).
2025-05-28 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for LSL Pharma Group Inc. for the three-month periods ended March 31, 2025, and 2024. It contains comprehensive financial statements (Balance Sheet, Statement of Loss, Statement of Changes in Equity, Statement of Cash Flow) and detailed notes to the financial statements. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. Q1 2025
2025-05-28 English
News release - English.pdf
Earnings Release Classification · 91% confidence The document is a press release from the company announcing its fourth quarter and full year 2024 financial results, presenting summary metrics (revenues, EBITDA, net income) in bullet form, corporate developments, and subsequent events. It does not contain the full annual or interim report (MD&A and financial statements are referenced as available elsewhere) but rather provides key highlights of periodical results. This format and content match an Earnings Release (initial announcement of quarterly/periodical financial results). FY 2024
2025-05-01 English
News release - English.pdf
Capital/Financing Update Classification · 75% confidence The document is a corporate news release announcing a definitive option agreement on the Arikepay project, detailing share issuances, cash payments, and milestone obligations. It is not an earnings release, call transcript, or statutory report; instead, it describes a financing-style arrangement (issuance of shares and receipt of cash/exploration commitments) to advance its project. This fits the “Capital/Financing Update” category (CAP).
2025-04-23 English
Notice of the meeting and record date - French.pdf
Regulatory Filings Classification · 75% confidence The document is an electronic notice from TSX Trust confirming transmission of the record date and meeting date notice for the annual and extraordinary shareholder meeting of Groupe LSL Pharma Inc. It provides ISIN, CUSIP, meeting date, record dates, and related procedural details. It is not the actual proxy materials or AGM presentation, nor is it reporting voting results. It serves as a regulatory filing to exchanges and regulators. It does not fit specific categories like PSI (proxy statement itself) or DVA (voting results), so it falls into the fallback “Regulatory Filings” category.
2025-04-07 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.